Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis.

摘要: Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took standardised extract (SFE) daily for eight months clinical phase IIa trial (NCT01450124) age- gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes serum neurofilament light chain levels were correlated changes the profiles RR-MS cohort. Eight out 44 analysed LMs significantly reduced during an eight-month treatment period SFE seven these significant derive 5-lipoxygenase (5-LO) pathway. Baseline 12- 15-LO products elevated exhibited disease activity (EDA) compared no-evidence-of-disease-activity (NEDA) could predict response prediction model at baseline. Oral with reduces 5-LO-derived period. Treatment SFE, however, seems related 12-,15-LO cyclooxygenase product before exposure. Further studies should confirm their biomarker potential treatment.